The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
CGHS would give robust coverage to pensioners and with new innovations and practices
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Plans to double its manufacturing footprint to bolster the growth
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Subscribe To Our Newsletter & Stay Updated
